Nuvation Bio (NUVB) Share-based Compensation (2020 - 2026)

Nuvation Bio (NUVB) has reported Share-based Compensation for 7 consecutive years, with $109000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation fell 98.61% year-over-year to $109000.0; the TTM figure through Mar 2026 stood at $28.1 million (down 19.78% YoY), while the FY2025 annual figure was $51.3 million, up 5.99% from the prior year.
• Share-based Compensation eased to $109000.0 in Q1 2026 per NUVB's latest filing, from $8.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $12.0 million in Q2 2025 and bottomed at -$9.1 million in Q4 2022.
• Historically, Share-based Compensation has averaged $5.4 million across 5 years, with a median of $5.5 million in 2023.
• On a YoY basis, Share-based Compensation climbed as much as 128.42% in 2022 and fell as far as 426.18% in 2022.
• Nuvation Bio's Share-based Compensation stood at -$9.1 million in 2022, then surged by 159.47% to $5.4 million in 2023, then jumped by 87.61% to $10.2 million in 2024, then fell by 21.6% to $8.0 million in 2025, then sank by 98.64% to $109000.0 in 2026.
• Business Quant data shows NUVB's Share-based Compensation at $109000.0 in Q1 2026, $8.0 million in Q4 2025, and $8.0 million in Q3 2025.